Trials / Terminated
TerminatedNCT01798576
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 282 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing direct-acting antivirals in participants with chronic hepatitis C who failed previous treatment. Participants will be followed for the duration of their treatment (24, 48 or 72 weeks) and for 24 weeks of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon alfa-2a | Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling. |
| DRUG | Ribavirin | Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling. |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2013-02-26
- Last updated
- 2016-09-15
Locations
1 site across 1 country: Romania
Source: ClinicalTrials.gov record NCT01798576. Inclusion in this directory is not an endorsement.